ARTICLE | Distillery Therapeutics
Agonizing TrkB to restore cognitive function after chemotherapy
June 19, 2019 8:06 PM UTC
INDICATION: Cognitive dysfunction
Agonizing TrkB in patients treated with methotrexate chemotherapy could induce myelination and treat chemotherapy-induced cognitive impairment. Methotrexate exposure blocks activity-related myelination, which supports adaptive neurological function. In mice that had been administered methotrexate, a small molecule TrkB partial agonist reversed thinning of myelin sheaths in the brain and reduced cognitive impairment as assessed with a behavioral test evaluating attention and short-term memory...
BCIQ Target Profiles